QR Code

Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC

Background & Aims: Fibroblast growth factor 21 (FGF21) is a crucial regulator of cell metabolism. Tumour-secreted FGF21 has shown immune-checkpoint factor functions, and high FGF21 levels are associated with a poor prognosis for patients. However, its prognostic value and impact on treatment res...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Risako Kohya, Goki Suda, Masatsugu Ohara, Shunichi Hosoda, Takuya Sho, Makoto Chuma, Atsumasa Komori, Yuki Kugiyama, Yutaka Yasui, Kaoru Tsuchiya, Masayuki Kurosaki, Joji Tani, Shun Kaneko, Mina Nakagawa, Yasuhiro Asahina, Shinya Maekawa, Nobuyuki Enomoto, Yoshiya Yamamoto, Masaru Baba, Ren Yamada, Takashi Sasaki, Tomoka Yoda, Sonoe Yoshida, Qingjie Fu, Zijian Yang, Osamu Maehara, Shunsuke Ohnishi, Yoshimasa Tokuchi, Takashi Kitagataya, Naoki Kawagishi, Masato Nakai, Mitsuteru Natsuizaka, Koji Ogawa, Naoya Sakamoto
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Elsevier 2025-05-01
Rangatū:JHEP Reports
Ngā marau:
FGF21
Atezolizumab
Bevacizumab
Hepatocellular Carcinoma
Immune-checkpoint inhibitor
Prognosis
Urunga tuihono:http://www.sciencedirect.com/science/article/pii/S2589555925000412
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite